BR112022012385A2 - Método de preparação e aplicação de composto de agente de degradação de proteínas - Google Patents
Método de preparação e aplicação de composto de agente de degradação de proteínasInfo
- Publication number
- BR112022012385A2 BR112022012385A2 BR112022012385A BR112022012385A BR112022012385A2 BR 112022012385 A2 BR112022012385 A2 BR 112022012385A2 BR 112022012385 A BR112022012385 A BR 112022012385A BR 112022012385 A BR112022012385 A BR 112022012385A BR 112022012385 A2 BR112022012385 A2 BR 112022012385A2
- Authority
- BR
- Brazil
- Prior art keywords
- application
- preparation
- degrading agent
- agent compound
- protein degrading
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911342649 | 2019-12-23 | ||
| CN202010200682 | 2020-03-20 | ||
| CN202010496353 | 2020-06-03 | ||
| CN202011486334 | 2020-12-16 | ||
| PCT/CN2020/138572 WO2021129653A1 (zh) | 2019-12-23 | 2020-12-23 | 一种蛋白降解剂化合物的制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012385A2 true BR112022012385A2 (pt) | 2022-08-30 |
Family
ID=76573691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012385A BR112022012385A2 (pt) | 2019-12-23 | 2020-12-23 | Método de preparação e aplicação de composto de agente de degradação de proteínas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12441706B2 (enExample) |
| EP (1) | EP4083020A4 (enExample) |
| JP (1) | JP7791087B2 (enExample) |
| KR (1) | KR20220120629A (enExample) |
| CN (2) | CN114829342A (enExample) |
| AU (1) | AU2020414151A1 (enExample) |
| BR (1) | BR112022012385A2 (enExample) |
| CA (1) | CA3162523A1 (enExample) |
| CL (1) | CL2022001724A1 (enExample) |
| CO (1) | CO2022010305A2 (enExample) |
| EC (1) | ECSP22056811A (enExample) |
| IL (1) | IL294225B1 (enExample) |
| JO (1) | JOP20220159A1 (enExample) |
| MX (1) | MX2022007885A (enExample) |
| PE (1) | PE20230114A1 (enExample) |
| PH (1) | PH12022551571A1 (enExample) |
| TW (1) | TWI755992B (enExample) |
| WO (1) | WO2021129653A1 (enExample) |
| ZA (1) | ZA202208051B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| CR20230007A (es) | 2020-06-12 | 2023-06-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto de ftalazinona, y método de preparación y uso médico de este. |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| IL301690A (en) * | 2020-10-16 | 2023-05-01 | Dana Farber Cancer Inst Inc | Piperidinyl small molecule degraders of helios and methods of use |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| CA3226162A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| AU2023300784A1 (en) * | 2022-06-30 | 2025-01-02 | Anhorn Medicines Co., Ltd. | Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same |
| WO2024012570A1 (zh) * | 2022-07-15 | 2024-01-18 | 西藏海思科制药有限公司 | 一种含氮杂环衍生物及其组合物和药学上的应用 |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CN107709290B (zh) | 2015-04-21 | 2023-02-28 | Gtx公司 | 选择性雄激素受体降解剂(sard)配体和其使用方法 |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN110506039A (zh) * | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| CA3042297A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| WO2018098280A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| CN110194762B (zh) | 2018-02-27 | 2021-09-10 | 中国科学院上海药物研究所 | 酞嗪酮类衍生物、其制备方法和用途 |
| CN112390852B (zh) | 2019-08-14 | 2022-10-18 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的化合物及其制备方法和应用 |
| CN112457366B (zh) | 2019-09-06 | 2024-03-19 | 江西济民可信集团有限公司 | 作为蛋白降解剂的并环类化合物及其制备方法和应用 |
| CN112457367B (zh) | 2019-09-06 | 2022-08-23 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的连环类化合物及其制备方法和应用 |
| CN118930604A (zh) | 2019-09-29 | 2024-11-12 | 江西济民可信集团有限公司 | 作为蛋白降解剂杂环类化合物及包含其的药物组合物和应用 |
| CN113582974B (zh) | 2020-04-30 | 2022-05-17 | 江西济民可信集团有限公司 | 一类作为蛋白降解剂的化合物及其制备方法和医药用途 |
| CR20230007A (es) | 2020-06-12 | 2023-06-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto de ftalazinona, y método de preparación y uso médico de este. |
-
2020
- 2020-12-23 CN CN202080087926.2A patent/CN114829342A/zh active Pending
- 2020-12-23 TW TW109145818A patent/TWI755992B/zh active
- 2020-12-23 KR KR1020227025429A patent/KR20220120629A/ko active Pending
- 2020-12-23 US US17/788,154 patent/US12441706B2/en active Active
- 2020-12-23 IL IL294225A patent/IL294225B1/en unknown
- 2020-12-23 EP EP20908128.0A patent/EP4083020A4/en active Pending
- 2020-12-23 WO PCT/CN2020/138572 patent/WO2021129653A1/zh not_active Ceased
- 2020-12-23 AU AU2020414151A patent/AU2020414151A1/en active Pending
- 2020-12-23 CA CA3162523A patent/CA3162523A1/en active Pending
- 2020-12-23 PH PH1/2022/551571A patent/PH12022551571A1/en unknown
- 2020-12-23 CN CN202011545626.2A patent/CN113087704B/zh active Active
- 2020-12-23 JP JP2022539058A patent/JP7791087B2/ja active Active
- 2020-12-23 MX MX2022007885A patent/MX2022007885A/es unknown
- 2020-12-23 BR BR112022012385A patent/BR112022012385A2/pt unknown
- 2020-12-23 PE PE2022001313A patent/PE20230114A1/es unknown
-
2022
- 2022-06-20 JO JOP/2022/0159A patent/JOP20220159A1/ar unknown
- 2022-06-22 CL CL2022001724A patent/CL2022001724A1/es unknown
- 2022-07-19 ZA ZA2022/08051A patent/ZA202208051B/en unknown
- 2022-07-20 EC ECSENADI202256811A patent/ECSP22056811A/es unknown
- 2022-07-21 CO CONC2022/0010305A patent/CO2022010305A2/es unknown
-
2025
- 2025-08-15 US US19/301,909 patent/US20250376463A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113087704B (zh) | 2023-09-08 |
| US20230111119A1 (en) | 2023-04-13 |
| US12441706B2 (en) | 2025-10-14 |
| KR20220120629A (ko) | 2022-08-30 |
| PH12022551571A1 (en) | 2023-11-20 |
| WO2021129653A1 (zh) | 2021-07-01 |
| US20250376463A1 (en) | 2025-12-11 |
| JOP20220159A1 (ar) | 2022-06-20 |
| IL294225B1 (en) | 2026-02-01 |
| CO2022010305A2 (es) | 2022-08-09 |
| TWI755992B (zh) | 2022-02-21 |
| EP4083020A1 (en) | 2022-11-02 |
| CN113087704A (zh) | 2021-07-09 |
| ZA202208051B (en) | 2023-11-29 |
| CL2022001724A1 (es) | 2023-02-24 |
| JP2023508097A (ja) | 2023-02-28 |
| EP4083020A4 (en) | 2024-01-24 |
| CN114829342A (zh) | 2022-07-29 |
| JP7791087B2 (ja) | 2025-12-23 |
| AU2020414151A1 (en) | 2022-08-25 |
| MX2022007885A (es) | 2022-09-19 |
| ECSP22056811A (es) | 2022-12-30 |
| IL294225A (en) | 2022-08-01 |
| CA3162523A1 (en) | 2021-07-01 |
| PE20230114A1 (es) | 2023-01-27 |
| TW202128662A (zh) | 2021-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012385A2 (pt) | Método de preparação e aplicação de composto de agente de degradação de proteínas | |
| JOP20220155A1 (ar) | مشتقات البيرازول مفيدة كعوامل مضادة للسرطان | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| BR112022010254A2 (pt) | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio | |
| SA520411222B1 (ar) | مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| EP4071149A3 (en) | Heterocyclic compounds and uses thereof | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| BR112022006507A2 (pt) | Compostos heterocíclicos de arilmetileno como bloqueadores de canais de agitador de potássio kv1.3 | |
| AU2018274378A1 (en) | Compound used as autophagy regulator, and preparation method therefor and uses thereof | |
| MY208400A (en) | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof | |
| BR112023020274A2 (pt) | Método de preparo de composto bicíclico e aplicação como agente antifúngico | |
| EP4249005A3 (en) | 18f-labeled triazole containing psma inhibitors | |
| EA202192845A1 (ru) | Новые композиции, содержащие мелфлуфен | |
| AU2018341781A8 (en) | Fused ring derivative as A2A receptor inhibitor | |
| EA201790496A1 (ru) | Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm | |
| SA521431279B1 (ar) | D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي | |
| BR112021026509A2 (pt) | Composto de isoxazolina, seu método de preparação e sua aplicação | |
| BR112018069504A2 (pt) | composto de sultam e método de aplicação do mesmo | |
| MX379576B (es) | Derivados de azetidina | |
| BR112022008647A2 (pt) | Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo | |
| NZ796802A (en) | Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof | |
| PH12022550529A1 (en) | Magl inhibitor, preparation method and use thereof |